Map Home
Type / to search with text or keywords
/
keyboard shortcut: Type "/" on your keyboard for a quick search
Search button
Loading...
Loading...
Scroll left
Grants
Citations
H-Index
Patents
News
Books
Scroll right
Collapse sidebar
Data issues & feedback
Adjust height of sidebar
KMap
Funding Agency
For Profit
(FP)
788.7M Funding
667 People
1718 Grants
People
Conrad Clemens
Health Promotion Sciences
Senior Associate Dean
Abhijeet Kumar
Medicine
Associate Professor, Medicine - (Clinical Scholar Track)
Kirsten Anderson
Senior VP Health Sciences
Research Compliance Administrator IV
Franz Rischard
Medicine
Professor
Sasha Taleban
Medicine
Associate Professor
Elena Young
COM Phx Internal Medicine
Research Compliance Manager II
Rachna Shroff
Medicine
Professor
VENKATESH KUMAR ARIYAMUTHU
Medicine
Associate Professor, Medicine - (Clinical Scholar Track)
Klearchos Papas
Surgery
Professor
Alejandro Recio Boiles
Medicine
Assistant Professor, Medicine - (Clinical Scholar Track)
Recent Grants
A Phase 3, Open-Label, Randomized Study to Compare the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 X Anti-CD3 BiSpecific Antibody, Versus Investigator's Choice in Previously Untreated
Active
·
2024
·
$7.5M
Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure (DRAIN-HF)
Active
·
2024
·
$2.9M
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 As Single-Agent And Combination Therapy In Subjects With Inoperable Locally Advanced or Metastatic Solid Tumors
Active
·
2024
·
$1.6M
A Phase 3 Randomized Clinical Study of MK-4280A (coformulated favezelimab (MK-4280) plus pembrolizumab (MK-3475)) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory C
Active
·
2024
·
$1.3M
A Phase 3, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Compared to R2 in Subjects with Relapsed or Refractory Follicular Lymphom
Active
·
2024
·
$1.2M
Supporting Communities and Small Business by Conducting Risk and Vulnerability Assessments through Student Experiential Learning Opportunities
Active
·
2024
·
$1M
A Phase Ill, Multicentre, Randomised, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety, and Tolerability of a Single Administration Of Comp360 in Participants With Treatment-
Active
·
2024
·
$994.4K
A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects with Moderate to Severe Hidradenitis Suppurativa Who Have
Active
·
2024
·
$964K
A Prospective Randomized Multicenter Global Study Comparing Pulsed Field Ablation versus Anti-Arrhythmic Drug Therapy as a First Line Treatment for Persistent Atrial Fibrillation
Active
·
2024
·
$945.6K
Study to Evaluate Safety, Efficacy and Tolerability of ABBV-950 for the Treatment of Upper Limb Spasticity in Adult Post-Stroke Patients
Active
·
2024
·
$822.1K
